PRECISEU Matchmaking Platform

20 Oct 2025 – 31 Jan 2026 | Barcelona, Spain

Register
Register
Register

Business OpportunityUpdated on 27 October 2025

Personalized Bone Regeneration via Immunomodulatory GBR/BSM Platforms

Principal Investigator at NMI Natural and Medical Sciences Institute

Reutlingen, Germany

About

We propose a novel approach to personalized bone regeneration by developing immunomodulatory Guided Bone Regeneration (GBR) membranes and Bone Substitute Materials (BSMs) tailored to each patient’s immune and healing profile. Unlike conventional “one-size-fits-all” solutions, our platform enables material-level personalization, not only in shape or size, but in biological function—guided by patient-specific biomarkers (e.g., cytokine levels, immune phenotypes). Advanced therapeutic medicinal products (ATMPs) proposed promising alternative therapeutic modalities by application of cell-based and tissue engineering approaches. Cell-based therapies are likely to be clinically supported by the new ATMPs, innovative fabrication processes, and enhanced surgical approaches. The development and standardization of methodologies is still a major challenge.

Stage

  • TRL 6

Topic

  • Injury, poisoning, other external causes
  • Musculoskeletal system, connective tissue
  • Other symptoms, deviant clinical findings
  • Regenerative medicine

Sector

  • ATMPs

Type

  • Research collaboration
  • Co-development
  • Clinical validation
  • Consortium partners

Organisation

NMI Natural and Medical Sciences Institute

Research Center

Reutlingen, Germany

Similar opportunities

  • Business Opportunity

    Preclinical Platform for ATMP Evaluation with Patient-Derived Microtumours (PDMs)

    • AI
    • TRL 6
    • ATMPs
    • Genomics
    • Oncology
    • Proteomics
    • Health data
    • Diagnostics
    • Bioinformatics
    • Co-development
    • Regulatory expert
    • Consortium partners
    • Research collaboration
    • Neoplasms/cancer/oncology

    Martin Kriebel

    Group Leader (dep.) Cellular & Molecular Biology at NMI Natural and Medical Sciences Institute

    Reutlingen, Germany

  • Business Opportunity

    vitalera: Making Hospital-at-Home a Reality with AI

    • AI
    • TRL 8
    • Oncology
    • Physiology
    • Pediatrics
    • Licensing
    • Respiratory
    • Health data
    • Rare diseases
    • Rare diseases
    • Bioinformatics
    • Cardiovascular
    • Co-development
    • Digestive system
    • Consortium partners
    • Regenerative medicine
    • Research collaboration
    • External causes of morbidity, mortality
    • Injury, poisoning, other external causes
    • Pregnancy, childbirth and the puerperium
    • Musculoskeletal system, connective tissue
    • Other symptoms, deviant clinical findings
    • Diseases of the blood and immune disorders
    • Diseases of the nervous system / neurology
    • Mental and behavioural disorders / psychiatry /psychology

    Nuria Pastor

    General Manager at vitalera

    Barcelona, Spain

  • Business Opportunity

    AI-powered Healthcare with therapeutic red blood cells

    • AI
    • TRL 6
    • ATMPs
    • Health data
    • Diagnostics
    • Rare diseases
    • Rare diseases
    • Co-development
    • Clinical validation
    • Regenerative medicine
    • Endocrine/nutritional/metabolic diseases
    • Diseases of the nervous system / neurology
    • Mental and behavioural disorders / psychiatry /psychology

    Denis Demarais

    Founder and CEO at Rius Medical

    Waldachtal, Germany